Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Adelia Therapeutics","sponsor":"CYBIN","pharmaFlowCategory":"D","amount":"$15.7 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Signs Definitive Agreement To Acquire Adelia Therapeutics As Part Of Its Commitment To Strategic Growth","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Adelia Therapeutics"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enveric Biosciences Announces Closing of MagicMed Industries Acquisition","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Enveric Biosciences"},{"orgOrder":0,"company":"Invea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invea Therapeutics Announces Poster Presentations at Keystone Symposia Gut-Brain Axis and Digestive Disease Week (DDW2022)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Invea Therapeutics"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Pritzker Neuropsychiatric Disorders Research Consortium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Verge Genomics"},{"orgOrder":0,"company":"Chemify","sponsor":"Prepaire Labs","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chemify Partners with Prepaire Labs to Apply Ground-breaking Chemistry AI-Robotics to Radically Accelerate the Discovery of Non-Addictive Opioids","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Undisclosed","graph2":"Chemify"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Chemify will design and discover novel non-addictive Opioids as pain modulators, tackling Opioid addiction directly by combining Chemify's breakthrough programmable chemistry platform with Prepaire’s integrated novel open collaboration drug discovery platform.

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Prepaire Labs

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Partnership January 18, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration, Verge will use CONVERGE®, its all-in-human, AI-powered platform, to identify novel therapeutic targets by using data generated from postmortem brain tissue provided by schizophrenia patients and healthy donors.

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Pritzker Neuropsychiatric Disorders Research Consortium

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 31, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Research demonstrates advantage of using AI and ML to deconvolute bidirectional communication network of physical, cellular, and biochemical connections between central nervous system, enteric nervous system, immune system, and GI tract, known as the Gut-Brain Axis.

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Enveric intends to expand into a next-generation neuroscience drug discovery platform of novel psychedelics that addresses the large unmet mental health challenges related to CNS indications such as Cancer Related Distress, PTSD, anxiety, depression and pain.

            Lead Product(s): Psychedelic Derivative Compound

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: Enveric Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition September 17, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Adelia’s leadership team brings deep clinical and commercialization experience, including past commercial success in psychedelics through the development of proprietary ketamine analogs as well as strong understanding of the underlying science.

            Lead Product(s): Ketamine analogs

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: CYBIN

            Deal Size: $15.7 million Upfront Cash: Undisclosed

            Deal Type: Acquisition December 07, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY